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Abstract
Purpose Radical prostatectomy and complementary extended
pelvic lymph node dissection (ePLND) of sentinel lymph
nodes (SNs) and non-sentinel lymph nodes (LNs) at risk of
containing metastases are increasingly being performed using
high-tech robot-assisted approaches. Although this technolog-
ical evolution has clear advantages, the physical nature of
robotic systems limits the integrated use of routine
radioguided surgery technologies. Hence, engineering effort
in robotics are focused on the integration of fluorescence guid-
ance technologies. Using the hybrid SN tracer indocyanine
green-99mTc-nanocolloid (radioactive and fluorescent), for
the first time in combination with a robot-integrated laparo-
scope, we investigated whether the robot-assisted approach
affects the accuracy of fluorescence detection of SNs identi-
fied preoperatively using nuclear medicine.
Methods The study included 55 patients (Briganti nomogram-
based risk >5 % on LN metastases) scheduled for robot-
assisted radical prostatectomy, SN biopsy and ePLND.
Following indocyanine green-99mTc-nanocolloid injection,
preoperative nuclear imaging (lymphoscintigraphy and
SPECT/CT) was used to locate the SN(s). The fluorescence
laparoscope was used intraoperatively to identify the SN(s)
with standard fluorescence settings (in 50 patients) and with
customized settings (in 5 patients). The number and location
of the SNs, the radioactive, fluorescence (both in vivo and ex
vivo) and tumour status of the resected SNs/LNs, and postop-
erative complications were recorded and analysed.
Results Combined, preoperative lymphoscintigraphy and
SPECT/CT imaging identified 212 SNs (median 4 per pa-
tient). Intraoperative fluorescence imaging using standard
fluorescence settings visualized 80.4 % (148/184 SNs; 50 pa-
tients; ex vivo 97.8 %). This increased to 85.7 % (12/14 SNs;
5 patients; ex vivo 100 %) with customized fluorescence set-
tings. SPECT/CT images provided guidance towards the re-
sidual SNs. Ex vivo all removed SNs were radioactive. SNs
were tumour-positive in 25.4 % of patients (14/55; false-
negative rate 7 %, 1/14 patients). In ten patients, the SN was
the only tumour-positive LN. Surgical complications were
minimal.
Conclusion Directly linking 3D preoperative nuclear imaging
information on SNs to a robot-integrated fluorescence laparo-
scope improved the surgeon’s use of the technology and did
not influence the sensitivity or morbidity of the procedure. To
our surprise, however, the detection rates with the current
fluorescence camera did not improve.
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Introduction
In complex anatomies, accurate preoperative mapping of sen-
tinel nodes (SNs) using nuclear medicine (lymphoscintigraphy
with or without SPECT/CT) and intraoperative radioguidance
are vital for planning and performing nodal resection [1, 2].
Imaging in combination with the intraoperative use of gamma
probes and/or portable gamma cameras has been shown to be
valuable not only in patients with melanoma, penile, vulvar and
breast cancer [3–5], but also during the sampling of pelvic SNs
originating from prostate cancer [6–8]. With SPECT/CT it has
become possible to accurately identify the anatomical location
of SNs inside or outside the extended pelvic lymph node dis-
section (ePLND) template, and subsequently this information
can be used for surgical planning.
In parallel with the technical evolution of nuclear
medicine-based imaging, there has been a shift towards
robot-assisted laparoscopic procedures in urology, and in par-
ticular for prostate cancer. Unfortunately, this shift has resulted
in a mismatch between the two disciplines. Moreover, in ro-
botic surgery, the urologist is no longer present alongside the
patient, limiting the control he/she has on the use of imaging
technologies without robot assistance such as the gamma
probe [9]. At the same time, the robot arms physically restrict
access for larger devices such as portable gamma cameras. On
the positive side, new-generation laparoscopes can be
equipped with an integrated fluorescence imaging option
[10–12]. Hence, integration of this technology in the robotic
workflow currently seems to be more straightforward.
Fluorescence guidance towards SNs and non-sentinel lymph
nodes (LNs) has been achieved in a robotic setting through the
use of an additional fluorescence laparoscope and via a robot-
in tegrated f luorescence laparoscope [9–11, 13] .
Unfortunately, the fluorescent signal has very limited tissue
penetration, meaning that more deeply lying SNs/LNs may be
missed when using fluorescence imaging alone [14]. Even
worse, extensive surgery in the quest for a fluorescent signal
may lead to an increase in surgical complications.
In 2009, the hybrid tracer indocyanine green- 99mTc-
nanocolloid (ICG-99mTc-nanocolloid) was clinically intro-
duced for SN biopsy. This tracer was designed to extend the
European standard in nuclear medicine-based SN identifica-
tion, 99mTc-nanocolloid, with intraoperative fluorescence
guidance [10, 15–17]. With this development, the strengths
of radioguided procedures (e.g. a high sensitivity and in-
depth view of the SNs) are complemented by detailed real-
time, but superficial, fluorescence guidance towards the pre-
operatively identified SNs. In combination with the introduc-
tion of an additional fluorescence laparoscope, the hybrid
concept has provided a significant step forward in connecting
preoperative lymphatic mapping and real-time intraoperative
fluorescence-based SN identification [9]. However, the fact
that the bedside assistant had to introduce and control the
fluorescence laparoscope, rather than the operating urologist,
was considered a limiting factor of this approach. We thus
hypothesized that use of a robot-integrated fluorescence lapa-
roscope could increase the level of control the operating urol-
ogist has, and could thus help increase the success rate in
resecting preoperatively identified SNs via fluorescence guid-
ance. To place these findings in perspective, the tumour-
positive rate, sensitivity, false-negative rate and complication
rate of SN biopsy using the this approach was evaluated and
compared to SN biopsy in a historical cohort [9].
Materials and methods
Patients
Between January 2014 and July 2015, 50 patients with a
Briganti nomogram-based risk of >5 % of LN metastases
were included [18]. These patients were evaluated with
the robot-integrated fluorescence laparoscope (standard
settings). Between July 2015 and September 2015 anoth-
er 5 patients were included for evaluation of the custom-
ized fluorescence imaging settings. All patients were
scheduled for robot-assisted radical prostatectomy,
ePLND and SN removal using the hybrid tracer, and
provided written informed consent. The characteristics
of the two groups of included patients are shown in
Table 1.
Preoperative SN mapping
Tracer preparation, injection and preoperative imaging
(lymphoscintigraphy and SPECT/CT) were performed as pre-
viously described by KleinJan et al. [9].
Briefly, the hybrid tracer 99mTc-nanocolloid was prepared
by adding 2.0 mL pertechnetate (approximately 300 MBq) to
a vial of nanocolloid (GE Healthcare, Eindhoven,
The Netherlands). ICG (0.05 mL, 5.0 mg/mL: PULSION
Medical, Feldkirchen, Germany) was then added to the vial
of 99mTc-nanocolloid. The total volume was subtracted from
the volume of the vial and saline was added to reach a total
volume of 2.0 mL in the syringe, after which the tracer was
injected into the prostate under transrectal ultrasound guid-
ance. The injection was followed by preoperative
lymphoscintigraphy (15 min and 2 h after injection) and
SPECT/CT imaging directly after acquisition of the late
lymphoscintigram. After imaging acquisition the nuclear
medicine physician determined the number and location of
the SNs.
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Surgical (imaging) tools
For the surgical procedure a da Vinci Si system (Intuitive
Surgical, Sunnyvale, CA, USA) with an integrated Firefly
fluorescence laparoscope was used. Via the goggles of the
master console, images obtained with the laparoscope are pre-
sented to the urologist. Using the controllers of the console the
urologist is able to switch between the white light imaging
mode and the fluorescence imaging mode of the fluorescence
laparoscope. In the initial 50 patients fluorescence imaging
with the standard settings was evaluated.
After a software upgrade (P9 software update) of the da
Vinci Si system, the urologist was able to manually adjust
the fluorescence illuminator settings. In this second set-up,
with which 5 patients were evaluated, the intensity of the
white light background in the fluorescence image was varied
Table 1 Patient characteristics
Group Total
SN+ ePLND SN+ ePLND,
customized settings
No. of patients 50 5 55
Age (years), median (IQR) 63 (58 – 68) 66 (62 – 68) 63 (59 – 68)
Preoperative PSA level (ng/mL),
median (IQR)
7.75 (5.44 – 12.18) 7.9 (4.8 – 23.35) 7.9 (5.46 – 12)
Clinical T stage, n (%)
1c 6 (12) – 6 (11)
2a 5 (10) – 5 (9)
2b 9 (18) 1 (20) 10 (18)
2c 14 (28) 1 (20) 15 (27)
3a 12 (24) 2 (40) 14 (25)
3b 4 (8) 1 (20) 5 (9)
Biopsy Gleason sum score, n (%)
6 3 (6) – 3 (5)
7 30 (60) 4 (80) 34 (62)
8 15 (30) 1 (20) 16 (29)
9 2 (4) – 2 (4)
Briganti score, median (IQR) 28 (21 – 53) 54 (20 – 68) 28 (21 – 50)
Clinical N stage, n (%)
N0 44 (88) 5 (100) 49 (89)
Nx 6 (12) – 6 (11)
Pathological T stage, n (%)
2a – 1 (20) 1 (2)
2b 3 (6) – 3 (5)
2c 37 (74) 2 (40) 39 (71)
3a 4 (8) 1 (20) 5 (9)
3b 4 (8) 1 (20) 5 (9)
4 1 (2) – 1 (2)
4a 1 (2) – 1 (2)
Pathological Gleason sum score, n (%)
6 6 (12) 1 (20) 7 (13)
7 35 (70) 2 (40) 37 (67)
8 7 (14) 1 (20) 8 (14)
9 2 (4) 1 (20) 3 (54)
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from 30 % (standard settings) to 15 % and 0 %. The visibility
of the fluorescence signal within the SNs was evaluated at
these three different settings.
Surgical procedure
Prior to the start of the operation, the operating urologist
viewed the SPECT/CT images using a DICOM viewer
(PACS Vue Solutions; Carestream Health, Rochester, NY).
The SNs identified on SPECT were again related to their an-
atomical context using the anatomical information provided
by the low-dose CT scan. This information was used to help
guide the positioning of the surgical tools and the fluorescence
laparoscope for optimal SN localization and resection.
Preopeatively identified SNs in a location with a high risk of
surgical complications were left in situ. The remaining SNs,
after initial preparation of the area of interest, were optically
identified by switching between white light imaging and fluo-
rescence imaging (Fig. 1). After excision of the SN, the sur-
gical bed was re-examined using a combination of white light
and fluorescence imaging.
To simplify the surgical workflow, based on the results of our
previous study [9], no laparoscopic gamma probe was used in-
traoperatively. However, ex vivo the gamma probe (Europrobe
2; Eurorad S.A., Eckbolsheim, France) was used to validate the
radioactive signature in the excised SNs/LNs. To confirm the
presence of fluorescence in the excised SNs, fluorescence imag-
ing was performed ex vivo using a fluorescence camera for open
surgery (PDE; Hamamatsu Photonics K.K., Hamamatsu, Japan).
The number and location of SNs identified preoperatively and
intraoperatively were recorded together with their in vivo and ex
vivo fluorescent and radioactive status.
Following SN excision, an ePLND was performed follow-
ed by the the radical prostatectomy. The ePLND included
dissection of LNs from the following areas: around the exter-
nal iliac artery and vein, within the obturator fossa, and sur-
rounding the internal iliac artery [19].
(Histo)pathological examination
(Histo)pathological analysis of the SNs, additional LNs from
the ePLND specimens and the prostate were performed as
previously described [9].
Follow-up
Complications occurring within 90 days of the operation were
recorded using the Clavien-Dindo classification and were eval-
uated in the initial 50 patients [20]. In the last 5 patients evalu-
ated follow-up was not sufficiently long for them to be included
in the postoperative evaluation. The findings were compared to
those reported in our previous study in which we reported on
fluorescence guidance without robotic integration [9].
Statistical analysis
Statistical analysis was performed using SPSS Statistics, ver-
sion 22 (SPSS Inc., Chicago, IL). A p - value <0.05 was
Fig. 1 Fluorescence-based SN identification: a white light image; b fluorescence-based image
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considered significant. For continuous variables, the mean or
median and interquartile ranges (IQR) are presented. For dis-
crete variables, frequencies and percentages are reported. The
Welch two-sample t - test was used to compare the preopera-
tive Briganti scores, and the number of removed SNs and LNs
in the patients in this study and in the patients in the previous
study [9]. A Fisher’s exact test was used to compare the tu-
mour positivity rate (pN0 or pN1), and to evaluate differences
in postoperative complications between the initial 50 patients
included in this study and the patients in the previous study
[9].
The false-negative rate was calculated on a per-patient
basis using the following formula: false-negative
rate= [false-negative patients/(false-negative patients + true-
positive patients)] × 100 %. The sensitivity of the SN
biopsy procedure was also calculated on a per-patient
basis using the following formula: [no. of true-positive
patients/(no. of true-positive patients + no. of false-
negative patients)] × 100 %.
Results
Preoperative imaging
In 10 of the 55 patients (18.2 %) only unilateral drainage was
observed. In the overall group of 55 patients, 147 SNs were
identified on the lymphoscintigrams. An additional 65 SNs
were identified on SPECT/CT imaging, resulting in a total of
212 SNs (median 4 per patient, IQR 3 – 5) identified on preop-
erative imaging. Of these 212 preoperatively identified SNs, 55
(26 %) were located outside the ePLND area. These results are
specified for each patient group in Table 2 and in Fig. 2.
Intraoperative sentinel node identification
Of the 55 included patients, 54 were operated upon in a 1-day
protocol with a median of 5.04 h between tracer injection and
the start of the operation (IQR 4.33 – 5.20 h). One patient was
operated 18.40 h after tracer injection. The preoperatively
Table 2 SN detection and pathological evaluation
Group Total (n= 55)
SN+ ePLND (n = 50) SN+ ePLND, customized
settings (n= 5)
SNs detected preoperatively
On lymphoscintigraphy, total 137 10 147
On lymphoscintigraphy, per patient, median (IQR) 2.5 (1 – 4) 2 (1 – 3) 2 (1 – 4)
On SPECT/CT, total 4 (3 – 5) 2 (1 – 3.5) 4 (3 – 5)
On SPECT/CT, per patient, median (IQR) 201 11 212
SNs detected intraoperatively
Total removed 184 14 198
No. removed per patient, median (IQR) 4 (2 – 5) 1 (1 – 5) 4 (2 – 5)
No. not resected 36 0 36
No. additionally resected (as a result of SN cluster formation) 19 3 22
Pathological SN evaluation
No. harvested per patient, median (IQR) 4 (2 – 6) 1 (1 – 5) 4 (2 – 5)
Total no. 226 30 256
Total no. tumour-positive 17 0 17
Pathological LN evaluation
No. harvested from ePLND specimen per patient, median (range) 10 (8 – 14) 12 (7 – 22) 10 (8 – 15)
Total no. 582 69 651
Total no. tumour-positive (SNs +LNs) 41 0 41
Pathological SN+LN evaluation (total)
Total no. removed per patient (SN+ ePLND), median (IQR) 15.5 (12 – 20) 18 (12 – 28.5) 16 (12 – 20)
Total no. harvested SNs+LNs 807 99 906
Tumour-positive rate, no. (%) of patients pN1 1 4 (28) 0 (0) 14 (25)
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SPECT/CT images were analysed in the operating theatre
using an interactive DICOM viewer and provided a virtual
starting point for placement of the fluorescence laparoscope
in localizing the SNs via fluorescence guidance.
Of the 201 SNs identified in the initial 50 patients on pre-
operative imaging, 36 (17.9 %) were not pursued during the
operation. The decision not to resect these SNs was made on
the basis of its anatomical location or relationship to close
structures, such as presacral and pararectal SNs located close
to the rectum or SNs located behind vascular structures such
as the internal iliac artery, external iliac artery or vessels in the
para-aortal region (Fig. 2c).
As a result of cluster formation, 19 extra SNs were surgi-
cally resected based on fluorescence identification. These
clustered SNs were seen as one Bhotspot^ on SPECT, but
the CT scan indicated multiple LNs at the location of the
hotspot. A total of 148 SNswere removed using intraoperative
fluorescence guidance (this was 80.4 % of the 184 surgically
resected SNs; Table 2). After removal, ex vivo gamma tracing
confirmed excision of these SNs.
The 19.6 % of SNs that could not be resected using fluo-
rescence guidance were resected from the ePLND samples
based on the anatomical information provided by the
SPECT/CT images and ex vivo gamma tracing and
fluorescence imaging. More detailed ex vivo analysis of the
ePLND samples allowed fluorescence identification of 97.8%
(180) of the 184 SNs resected and detection of the radioactive
signal in 100 % of the SNs.
In the five patients in whom the tunable fluorescence im-
aging settings were evaluated, as well as the 11 preoperatively
identified SNs, 3 more SNs (part of a cluster of SNs) were
removed under fluorescence guidance (Table 2). Of the 14
SNs, 11 (78.6 %), 11 (78.6 %) and 12 (85.7 %) were visual-
ized at 30 %, 15 % and 0 % white light, respectively (ex vivo,
100% of the SNswere fluorescent and radioactive). The effect
of the light settings on the fluorescence image quality is shown
in Fig. 3.
Because the fluorescence laparoscope is an integral part of
the da Vinci Si system, the urologist manoeuvred and placed
the fluorescence laparoscope independently of the surgical
assistant, a feature that had a positive influence on the surgical
logistics.
Pathological examination SNs and ePLND specimens
At pathology, 256 nodes were extracted from the 198 SN
specimens surgically excised from the 55 patients, (median 4
per patient, IQR 2 – 5). From the ePLND specimens a total of
651 LNs were removed, giving a median of 16 LNs per pa-
tient. The results are presented in more detail for each patient
group in Table 2.
Histopathological examination revealed tumour-positive
LNs in 25.4 % of patients (14 of 55 patients, total 41 tumour-
positive nodes). In 10 of these 14 pN1 patients (71.4%), the SNs
were the only tumour-containing nodes. In 3 patients, tumour-
positive LNs were also found next to the tumour-positive SNs.
The result in one patient was false-negative. In this patient the
SN was tumour-negative but a metastasis was detected in a LN
from the ePLND tissue specimen, and this LN was not fluores-
cent or radioactive during surgery. The false-negative rate in this
study was therefore 7.1 % (1/14). The sensitivity of SN biopsy
in this cohort was good: the procedure correctly staged 13 of 14
node-positive patients (92.9 %). In a previously reported group
of patients with similar Briganti scores, we found a tumour-
positive node rate of 20 % (8/40 patients) [9]. Compared to
the previous study, in the current study, significantly more LNs
were removed per patient (median 16 vs. 12; p<0.001) and
5.4 % more node-positive patients were identified (14/55 pa-
tients; i.e. 25.4 % vs. 20 %; p=0.6). There was no significant
difference in the a priori likelihood of LN metastasis (p=0.3).
Follow-up (complications)
No significant differences were found in the postoperative
complication rates between the patients in the current study
and those in the previous study (Table 3) [9]. Changing and
Fig. 2 Locations of SNs and LNs detected intraoperatively. a, b SNs
located inside and outside the ePLND area (green in vivo fluorescent SNs,
yellow ex vivo identified SNs n=50). c SNs that could not be removed (red,
n=55). d, e SNs located in the additionally included five patients inside and
outside the ePLND area (green in vivo fluorescent SNs, yellow ex vivo
identified SNs). f Location of tumour-positive SNs (black right-sided SNs,
grey left-sided SNs). The images were generated using Visible Body soft-
ware (Argosy Publishing, Newton Upper Falls, MA)
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integrating the fluorescence laparoscope did not change the
postoperative complication rate.
Discussion
Integrating molecular imaging and robotic surgery is an im-
portant step in the evolution that is taking place in the treat-
ment of prostate cancer. In the current study, using a hybrid
(radioactive and fluorescent) SN tracer, findings from nuclear
medicine imaging were used to guide the surgical resection
using a robot-integrated fluorescence laparoscope. In some
patients, it was decided, based on the SPECT/CT information,
that some of the preoperatively identified SNs were not eligi-
ble for surgical removal. In the remaining patients, the ana-
tomical locations derived from the SPECT/CT images were
used to position the fluorescence laparoscope or, when
intraoperative fluorescence imaging did not provide accurate
SN identification, to guide resection of the SNs.
Robotic integration of fluorescence imaging gives the urol-
ogist more control over the use and positioning of the laparo-
scope, thus increasing his/her autonomy [21, 22]. To our sur-
prise, using the standard fluorescence imaging settings of the
robot-integrated fluorescence laparoscope, integration did not
convert into an improved in vivo fluorescence-based SN vi-
sualization rate. In fact, the percentage found was lower than
the rate we found previously in a setting where the bedside
assistant was responsible for placement of an external fluores-
cence laparoscope [9]. This difference seems to be the result of
differences in the camera technology used. However, it may
also have been caused by the shorter time spent by the urolo-
gist in exploring the area of interest. The last point – saving
surgical time to allow accurate fluorescence identification –
seems to be in line with our previous finding [9].
Nevertheless, the fluorescence imaging miss-rate of








SN+ ePLND (n= 50)




Lymphocele IIIa 1 (2) 2 (5) 3 (3)
Urinary tract infection II 2 (4) 2 (5) 4 (4)
Postoperative bowel obstruction II 1 (2) 1 (3) 2 (2)
Micturition obstruction
(Sachse ureterotomy)
IIIb 0 1 (3) 1 (1)
Hematoma of the ventral
abdominal wall
I 1 (2) 0 2 (9)
Postoperative infected abdominal
haematoma
II 1 (2) 1 (3) 2 (9)
Leakage of anastomosis I/III 2 (4) 0 (0) 2 (2)
Postoperative wound infection II 0 1 (3) 1 (1)
Epididymitis II 0 1 (3) 1 (1)
Hydronephrosis IIIa 0 1 (3) 1 (1)
Deep venous thrombosis II 1 (2) 0 1 (1)
Total 9 (18) 10 (25)* 19 (21)
Values are number (%) of patients
*p= 0.4
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15 – 20 % (in the 55 patients) means that with fluorescence
guidance alone a large number of SNs would have been
missed. Due to the hybrid nature of the tracer used, the radio-
active signature could be used to compensate for this short-
coming and to identify the additional SNs. Rather than using
cumbersome laparoscopic gamma tracing, which again has to
be performed by the bedside assistant, we used a more time
effective combination of ex vivo gamma tracing and SPECT/
CT images to guide resection of the residual SNs. Next to the
radioactive signatures, the fluorescent signatures we verified
ex vivo considerably increased the fluorescence-based SN de-
tection rate (>97 %). This finding emphasizes that the tissue
attenuation encountered in the in vivo situation limits the suc-
cess of the fluorescence guidance approach, rather than the
presence of tracer in the SNs. It also indicates that the backup
from SPECT/CT is of the utmost importance. In an ongoing
randomized controlled study we are evaluating these aspects
in more detail.
In the five patients in whom the fluorescence settings could
be adjusted, decreasing the percentage of white light, and thus
decreasing the level of anatomical detail in the fluorescence
image, helped improve the detection rate to 85.7 %. This im-
provement seems to contradict our previous findings. With a
different fluorescence laparoscope, the introduction of white-
light anatomical background information positively influ-
enced the intraoperative fluorescence-based identification rate
[9]. In this previous set-up we did not determine if the appli-
cation of flexible white-light settings could improve fluores-
cence detection rates even further. The increased time used for
the fluorescence detection at different light settings could also
have played influenced the detection rate. Based on the current
findings, an adjustable illuminator, wherein white light inten-
sity can be tailored, may most flexibly accommodate the urol-
ogist’s needs.
One may reason that increasing the proportion of
tumour-positive LNs resected will increase the likelihood
of the patient’s recovery from the disease. In this sense,
the 5.4 % greater rate of detection of tumour-positive
LNs and the higher sensitivity than in our previous study
(92.9 % vs. 75.0 %) [9] can be considered valuable.
However, we cannot fully attribute this result to the sur-
gical procedure. The tumour-positive LN detection rate
may partly also be affected by the increased number of
resected SNs and the pathological examination of the
specimens. SNs have a higher chance of containing
(micro)metastases and thus have a prognostic value [23]
and as such receive more careful pathological evaluation
including immunohistochemistry and cutting deeper
levels than LNs out of a dissection template [24–27].
A crucial aspect of the clinical introduction of a new
technology is the evaluation of the influence the technol-
ogy will have on clinical outcome. For fluorescence
guidance technologies such information is limited [14].
While one may reason that the SN biopsy procedure
increases the chance of postoperative complications, the
complication rate we observed was lower than in our
previous study (p= 0.4) [9]. In both studies this result
may in part be a consequence of using SPECT/CT plan-
ning to guide the procedure away from SNs located in
areas that may be associated with postoperative
complications.
The extensive introduction of new surgical technolo-
gies means that a need has been established for platforms
that allow the integration of numerous imaging findings
into the surgical workflow. In our view the da Vinci
robot platform may act as such a linking technology.
For example, robotic surgical goggles have been used
to introduce complementary intraoperative and preopera-
tive imaging findings as well as virtual/augmented reality
displays [12, 28]. Since in the current study it was not
possible to interactively examine the DICOM SPECT/CT
images in Tilepro® during the operation, the urologist
had to leave the console to examine them on a separate
DICOM viewing station. However, in another study we
have already provided a proof-of-concept that directly
linking SPECT/CT imaging information and fluorescence
imaging during robot-assisted procedures may provide
the next step in surgical guidance [29].
The hybrid tracer concept illustrated in this study and our
previous prostate cancer-related studies [9, 10, 30] provides a
valuable extension of routine SN identification. A similar
hybrid concept holds promise for (tumour-)targeted tracers
and may benefit from the set up we have applied for SN
identification. One example of a target that holds promise
for image-guided resection is prostate-specific membrane
antigen (PSMA), which is already routinely used in PET/
CT-based diagnostics (68Ga-PSMA-HBED-CC) and has been
successfully used for radioguided resection (111In-PSMA
I&T) [31]. Theoretically, a hybrid PSMA derivative [32]
would extend these efforts to accommodate (robot-
integrated) hybrid surgical guidance towards the primary
tumour margins, lymphatic metastases, and possibly even
other distant metastases.
Conclusion
Hybrid tracers help to integrate nuclear medicine and
fluorescence-guided robotic surgery, but the use of a robot-
integrated fluorescence laparoscope did not improve
fluorescence-based SN identification. Hence, 3D preoperative
imaging information from nuclear medicine remains crucial
for (virtual) planning of complex surgical resections of multi-
focal lesions. Further technical refinement of robot-integrated
guidance modalities in surgical procedures should improve
the relationship between preoperative and intraoperative im-
aging findings.
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